Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
8.24
0.00 (0.00%)
At close: Sep 4, 2026, 4:00 PM EDT
8.25
+0.01 (0.12%)
After-hours: Sep 4, 2026, 7:30 PM EDT
Agenus Revenue
Agenus had revenue of $34.52M in the quarter ending June 30, 2026, with 34.36% growth. This brings the company's revenue in the last twelve months to $132.69M, up 30.47% year-over-year. In the year 2025, Agenus had annual revenue of $114.20M with 10.37% growth.
Revenue (ttm)
$132.69M
Revenue Growth
+30.47%
P/S Ratio
2.80
Revenue / Employee
$1,638,185
Employees
81
Market Cap
370.97M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 114.20M | 10.73M | 10.37% |
| Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
| Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
| Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
| Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
| Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
| Dec 31, 2019 | 150.05M | 113.26M | 307.92% |
| Dec 31, 2018 | 36.78M | -6.09M | -14.21% |
| Dec 31, 2017 | 42.88M | 20.30M | 89.95% |
| Dec 31, 2016 | 22.57M | -2.24M | -9.04% |
| Dec 31, 2015 | 24.82M | 17.84M | 255.67% |
| Dec 31, 2014 | 6.98M | 3.93M | 129.13% |
| Dec 31, 2013 | 3.05M | -12.92M | -80.92% |
| Dec 31, 2012 | 15.96M | 13.20M | 479.17% |
| Dec 31, 2011 | 2.76M | -603.84K | -17.97% |
| Dec 31, 2010 | 3.36M | 25.17K | 0.75% |
| Dec 31, 2009 | 3.33M | 683.36K | 25.78% |
| Dec 31, 2008 | 2.65M | -2.90M | -52.25% |
| Dec 31, 2007 | 5.55M | 4.86M | 702.20% |
| Dec 31, 2006 | 692.14K | 62.16K | 9.87% |
| Dec 31, 2005 | 629.98K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Q32 Bio | 53.74M |
| Zentalis Pharmaceuticals | 26.87M |
| Abeona Therapeutics | 25.52M |
| X4 Pharmaceuticals | 15.85M |
| Opus Genetics | 9.86M |
| EyePoint | 2.79M |
| Palisade Bio | 500.00K |
AGEN News
- 7 days ago - Agenus to Participate in Upcoming September Investor Conferences - Business Wire
- 10 days ago - Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism - Business Wire
- 12 days ago - Agenus: No colorectal cancer recurrences observed at updated follow-up in trial - TheFly
- 12 days ago - Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer - Business Wire
- 27 days ago - Agenus price target lowered to $25 from $30 at H.C. Wainwright - TheFly
- 4 weeks ago - Agenus files to sell 77.98M shares of common stock for holders - TheFly
- 4 weeks ago - Agenus Registration statement: Registration filing - Filings
- 4 weeks ago - Agenus Earnings release: Q2 2026 - Filings